title: The post-BART anti-fibrinolytic dilemma?
authors.forename: W Scott
authors.initials: WS
authors.lastname: Beattie
authors.forename: Keyvan
authors.initials: K
authors.lastname: Karkouti
mesh_terms: D015119:Aminocaproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D006348:Cardiac Surgical Procedures; D006801:Humans; D019990:Perioperative Care; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D007611:Aprotinin; D015119:Aminocaproic Acid